Recent studies suggest that the Hi subunit of the carbohydrate recognition domain (Hi CRD) of the asialoglycoprotein receptor is used as an entry site into hepatocytes by hepatitis A and B viruses and Marburg virus. Thus, molecules binding specifically to the CRD might exert inhibition towards these diseases by blocking the virus entry site. We report here the identification of the epitope structure of Hi CRD to a monoclonal antibody by proteolytic epitope excision of the immune complex and highresolution MALDI-FTICR mass spectrometry. As a prerequisite of the epitope determination, the primary structure of the Hi CRD antigen was characterised by ESI-FTlCR-MS of the intact protein and by LC-MS/MS of tryptic digest mixtures. Molecular mass determination and proteolytic fragments provided the identification of two intramolecular disulfide bridges (seven Cys residues), and a Cys-mercaptoethanol adduct formed by treatment with ~-mercaptoethanol during protein extraction. The H1CRD antigen binds to the monoclonal antibody in both native and Cys-alkylated form. For identification of the epitope, the antibody was immobilized on N-hydroxysuccinimide (NHS)-activated Sepharose. Epitope excision and epitope extraction with trypsin and FTICR-MS of affinity-bound peptides provided the identification of two specific epitope peptides (5-16) and (17-23) that showed high affinity to the antibody. Affinity studies of the synthetic epitope peptides revealed independent binding of each peptide to the antibody.
Introduction
T he asialoglycoprotein receptor (ASGP-R) belongs to the C-type (calcium-dependent) class of lectins [1] and is located on hepatocytes of all mammalian organisms [2] . The receptor is a hetero-oligomer consisting of various ratios of the two homologous subunits HI and H2, which exhibit 58% sequence homology [3] . Both subunits are composed of a cytosolic N-tenninal domain, a single transmembrane segment, a stalk domain and a C-terminal carbohydrate recognition domain (CRD) (Figure I a) . The carbohydrate recognition domain of subunit HI (H I CRD) binds glycoproteins with terminal galactose (Gal) and N-acetylgalactosamine (GaINAc) motifs [4, 5] . The receptor provides clearance of circulating ligand glycoproteins by receptormediated endocytosis followed by degradation in the lysosome, and it is then recycled to the cell surface. Although both subunits are required for endocytosis of ligands, the carbohydrate binding activity was shown to be associated predominantly with HI [6] . Recent studies suggest that ASGP-R is used as an entry site into hepatocytes by hepatitis B virus, Marburg virus and hepatitis A virus [7, 8] . Thus, molecules that bind specifically to the carbohydrate recognition domain (CRO) might exert inhibitory effects towards these diseases by blocking the virus entry site. Knowledge of the epitope(s) of antibodies against HI CRO may contribute to the development of specific agents capable of blocking carbohydrate binding.
HI CRO consists of the amino acid residues (147-290) of full-length HI. The X-ray crystal structure of HI CRO (available at the POB accession number, I dv8) has been described for the amino acid residues 153-280, although the structures at the N-and C-ten11inal sequences (147-152) and (281 -290) were not identified as a result of thermal disorder [9) . According to the structural data, HI CRO is a globular protein comprising six ~ strands Wl -~6) and two fl helices of 10 and II residues, respectively ( Figure I b) . The protein contains seven cysteine residues for which two disulfide bridges have been described and a third disulfide bond proposed from the X-ray structure, and three Ca 2 + binding sites. The carbohydrate binding site comprises the amino acid residues Gln-239, Asp-241, Trp-243, Glu-252, Asp-253 and Asn-264 [10] [11] [12] . Although the carbohydrate binding site resides within residues 239-264, the complete amino acid sequence of the globular CRO structure is required as an immunogen for antibody production.
In the present study we have identified the epitope structure of a recombinant HI CRD antigen expressed in E. coli [ 13] to a specific monoclonal antibody, using proteolytic excision of the HI CRO immune complex and affinity mass spectrometry. As a basis for the epitope identification, the complete primary structure and intramolecular disulfide bridges of HI CRO were characterised by high-resolution FTICR mass spectrometry and LC-MS/MS. Affinity mass spectrometry approaches using proteolytic epitope excision and epitope extraction have been previously described in detail and applied in epitope identifications [14] [15] [16] [17] [18] [19] . In the general analytical method [14] [15] [16] [17] 19] , the immobilised ligand-binder (antigen-antibody) complex is subjected to limited proteolytic digestion, followed by mass spectrometric analysis of the eluted affinity-bound epitope peptide fragment (s). In the proteolytic step, the epitope is protected from digestion owing to the shielding of the ligand-binder interaction structure; hence, epitope excision on an immobilised immune complex is essential for isolation, specific dissociation and identification of the bound epitope. In a variation of this approach ("epitope extraction") the antigen ligand is first subjected to proteolytic digestion, and the mixture of peptide fragments is subsequently presented to the binder (antibody) [19) . In alternative approaches [20] [21] [22] , epitope identifications have been perfonned by proteolytic digestion in solution without iml11obilisation of the antigen-antibody complex, by utilizing the specific signal depletion of the complex preserved on the MALOI target. Here we show that the application of both epitope excision MS and epitope extraction MS provided the identification of a specific epitope structure at the N-terminal part of HI CRD, which is independent and remote from the carbohydrate binding site. In contrast to the binding of carbohydrates to HI CRD that requires the presence of calcium ions, antibody binding and epitope were found to be identical with and without the presence of calcium. Moreover, we show that the two synthesized N-terminal epitope peptides each exhibit independent affinity to the antibody. The determination of the epitope structure provides a molecular basis for approaches towards the development of specific inhibitors of the carbohydrate binding of HI.
Experimental

Preparation of H 1 CRD
The recombinant carbohydrate recogl11tlon domain of HI (H I CRD) was expressed in E. coli and purified by affinity chromatography and size exclusion chromatography as previously described [5, 23] . The cDNA comprised the amino acid residues 147-290 of the H I subunit of ASGPR and an initiator methionine (see sequence numbering of the recombinant HI CRD in the Supplementary Figure I) . Nterminal Edman sequence determination of the purified recombinant HI CRD, performed with a Procise-470 automated Edman sequencer (Applied Biosystems, Foster City, CA), showed the lack of the initiator methionine.
Reduction and Alkylation of Disuljide Bonds
Disulfide bridge reduction was performed by addition of a 50-fold molar excess of dithiothreitol (OTT) per cysteine residue followed by incubation at 56°C for I h. The samp le was then alkylated by incubation for I h at 25°C in the dark with a 2.5-fold molar excess of iodoacetamide (IAA) over OTT. Carboxymethylation was also carried out without prior cysteine reduction in order to modify on ly cysteine residues not involved in disulfide bridges.
Antibody Immobilization
The monoclonal antibody clone BO 1.4 [23] was dissolved in 0.2 M NaH C0 3 and 0.5 M NaCI coup ling buffer (PH 8.3) to a final concentration of 0.5 ~lg ~L -I . A 200 ~L aliquot of this solution was added to 66 mg dry NHS-activated 6-aminohexanoic acid-coupled Sepharose (Sigma, St. Louis, MO) and th e coup ling reaction performed for I h at 20°C. The coupling product was loaded into a '0.8 mL microcolumn (Mobitec, G6tti ngen, FRG) and washed sequentially with blocking (0 . 1 M aminoethanol, 0.5 M NaCI , pH 8.3) and washing solution (0.2 M CH]COONa 0.5 M NaCI, pH 4.0). Each washing step was perfomled with 24 mL (four times 6 mL) buffer and the procedure was repeated after I h incubation in blocking buffer.
Proteolytic Epitope Excision and Extraction
For epitope excis ion 50 ~lg solutions of H I CRD dissolved in 200 pL PBS (5 mM Na2HP04, 150 mM NaCI, pH 7.5) with and without the addition of 20 mM CaCl z were app lied to the affinity matrix. The column was gently shaken for 2 h to allow complete antigen binding, and unbound material was removed by washing with 10 mL PBS . Remaining affinitybound antigen was digested for 2 h at 37°C with 1 ~g tosyl phenylalanyl chloromethy l ketone (TPCK)-tTeated trypsin in 50 mM NH 4 HCO], or for 20 h with endoprotease G lu-C. Supernatant non-epitope containing peptides were removed by washing with 50 mL PBS. The immune complex was then dissociated by addition of 0.5 mL 0.1 % trifluoroacetic acid (TFA), pH -2. The column was gently shaken for 15 min at 20°C and the released epitope peptides collected in an Eppendorf cup for mass spectrometric analysis (Supplementary Figure 4 ). The column was regenerated by washing with 10 mL 0.1 % TFA ac id, pH -2, followed by 20 mL PBS. Epitope extraction was perfonned in the same manner by applying the proteolytic peptide mixture directly to the column. Desalting and concentration of the sample were perfonned by using ZipTip CI 8 pipette tips as previously described [24] .
Peptide Synthesis
Epitope peptides were synthesized by so lid-phase peptide synthesis (SPPS) according to the Fmoc/tBu strategy using a semi automated peptide synthesizer EPS 221 (Abimed, Langenfeld, Germany). All syntheses were performed on a NovaSyn TGR resin using N(n)-fluoreny lmethy loxycarbonyl (Fmoc)-protected amino acids in a fivefold molar excess relative to the amount of resin. Deprotection of the N (a)-amino gro up was carried out by addition of 2% 1,8-diazabicyclo [5.4 .0]undec-7-ene (DBU) and 2% piperidine in dimethylformamide (DMF). Activation was performed in 0.9 M (benzotriazo l-I-y loxy)trispyrrolidinophosphonium hexafluorophosphate (PyBOP) and 4 M N-methylmorpholine base (NMM) in DMF . C leavage of peptides from the resin was performed for 2-3 h at 20°C using a so lution containing 95% TFA, 2.5% triethylsilane and 2.5% deionized water.
Preparative reversed-phase high-performance liquid chromatography (RP-HPLC) purification of synthetic epitope peptides was carried out on a Knauer HPLC system (Knauer, Bad Homburg, Germany) using a preparative C 18 column GROM-SIL 120 ODS-4 SE with 10 ~m silica, 250 x 20 mm, 120 A pore size (Grom, Herrenberg-Kayh, Gennany). HPLC chromatograms were recorded by UV detection at 220 nm .
Mass Spectrometry
MALDI-FTICR mass spectrometry was performed with a Bruker APEX II FTICR mass spectrometer equ ipped with a 7 T magnet (Bruker Daltonik , Bremen, Germany) using an external Scout 100 MALDI ion source with fully automated X-Y target stage with pulsed collision gas [25 , 26] . The pulsed nitrogen laser was operated at 337 nm and MALDIgenerated ions cooled with the pulsing collision gas and directly captured into the hexapole ion guide. Ions generated by 20-30 laser shots were accumulated in the hexapole for 0.5-1 s at 30 V and extracted at 15 V. The matrix solution was prepared by dissolving 100 mg of 2,5-dihydroxybenzoic acid (DHB) in I mL acetonitrile/O.I % TFA in water (2: lv/v). A 0.5 ilL aliquot of matrix solution was deposited on the MALDI target, mixed with 0.5 ilL of sample solution and allowed to dry in ambient air. Mass spectra were obtained by using 10 laser shots for each scan and accumulating 32-64 scans. External calibration was performed by using the monoisotopic masses of singly protonated ions of human angiotensin I and 11, bradykinin, neurotensin, bovine insulin ~ chain (oxidized) and bovine insulin.
ESI-FTlCR-MS was performed with the Bruker APEX fI FTlCR mass spectrometer equipped with an APOLLO ESI source as previously described [19] . The sample was dissolved in a solution containing 50% methanol, 48% water and 2% acetic acid, and introduced at 2 ~LL min-I through a PEEK capillary to the spraying needle using a syringe pump. A voltage of -4200 V was applied between the metal-coated entry of the glass capillary and the grounded spray needle.
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The voltage applied at the end cap was -3800 V. Nitrogen was employed as nebulizing gas to stabilise the spray, and desolvation was facilitated by using N2 drying gas at 150°C. Before each measurement cycle, the source and the analyser cell were quenched for 50 ms. The ESI ions were passed through the glass capillary and from the capillary exit through the skimmer entering into the hexapole ion guide. The declustering potential (t:.CS) between capillary exit and skimmer was 60 V. After a predefined accumulation time in the hexapole (0.1 -2 s) the voltage of the extraction plate was reversed and ions were extracted for transmission to the ICR cell. External calibration was carried out using monoisotopic masses of angiotensin I fragment ions formed by in-source fragmentation; typical calibration mass accuracy was 0.5 ppm at a resolving power of approximately 80,000.
LC/MS analysis was performed with an Agilent (Waldbronn, Gennany) HP II 00 liquid chromatograph for binary gradient elution (model G 1312A) coupled to a Bruker Daltonik Esquire 3000+ ion trap mass spectrometer. A binary gradient system consisting of solvent A (0.1 % aqueous formic acid) and solvent B (80% acetonitrile, 0.1 % aqueous formic acid) was employed for LC separation; the sample was dissolved in solvent A at an injection volume of 5 ~LL. A 150 mm x 4.6 mm x 3 11m Discovery RP-18 column was used for peptide separation . All LC-MS data 
Results and Discussion
Characterisation of Primary Structure and Disulfide Linkages ofH1CRD
The I-II CRD of the receptor protein was expressed in E. coli and purified by affinity chromatography and size exclusion chromatog raphy as previously described [23 ] . Amino acid residues in the sequence of the recombinant HI CRD were numbered 1-144 as shown in Figure 2a and Supp lementary Figure I , and this sequence numbering is used throughout. As a precondition for the identification of the epitope, th e primary structure and disulfide linkages of HI CRD were initially characterised by ESI-FTIC R-MS of th e intact protein and LC-MS/MS of proteolytic digest mixtures. The molecular mass determination of HI CRD was performed (Figure 2b ) using an aliquot of the stock solu tion di luted to a final concentration of 6 ~lM. The determined experimental mass of 16,921.9093 is well in ag reement with th e calculated mass of th e protein of 16,922.5529, without methionine, containing two disulfide bridges, two reduced cysteine residues and one cysteine-p-mercaptoethanol (Cys-P-ME) adduct (Table I ). The lack of th e initiator methionine, a frequently observed modification of recombinant proteins [27] Supplementary Figures 3, 4) . The Cys-P-ME adduct was formed during extraction of the protein from the cell lysate and purification in the presence ofP-ME [23) .
The primary structure was further characterised by di gestion of native and alkylated HI CRD with trypsin and LysC protease fo llowed by MALDI -FTlC R-MS and LC-MS/MS of the proteolytic fragments. MALDl-FTICR mass spectra of the ttyptic digest of native and alkylated HI CRD are shown in Figure 3b -d and the identified peptides summarised in Table 2 and Supplementary Tab le 1. Twelve tryptic fragments (T 1-T 12) are formed by complete digestion of H I CRD (Figure 3a) , all of which were identified with the exception of the small peptides TI and T4 ( Table 2 ). The MALDI-FTICR mass spectra of the tryptic peptide mi xture of native HI CRD revealed the fragments T5 and Til , thereby allowing the presence of the disulfide bridge Cys-35-Cys-130 to be established. In addition, the accurate mass ofT2 ([M + HT", mlz 1470.6 15) was 2.02 lower than th e calculated mass with reduced Cys-6 and Cys-7 residues, thus corresponding to a vicinal disulfide bridge (Cys-6-Cys-7). The identification of th e vicinal disulfide bridge in th e fragment T2 was ascertained by reduction and carbamidomethy lation of cysteine residues and MALDI-FTlCR-MS (Figure 3d) . The a lkylated tryptic peptides each contained a sing le alkylated cysteine residue (T3 , Cys-18; Tl 0, Cys-l 22;
T il , Cys-130), whereas the fragment T2 contained two alkylated cysteine residues (Cys-6, Cys-7), thus confirming the vicinal disulfide bridge Cys-6-Cys-7 of HI CRD (Supplementaty Table I ). Additional confirmation was obtained Table 2 ). The identification of the disulfide bridge Cys-35-Cys-130 is in agreement with the X-ray structure [9] , although the Cys-6-Cys-7 linkage was not found by X-ray crystallography. The fonnation of a disulfide bond between adjacent cysteine residues is a relatively rare structural element, which is usually associated with a ~-turn of the protein backbone; vicina l disultide linkages, however, have been identified and stru cturally characterised in a number of proteins including enzy mes, receptors and toxins [28] [29] [30] . Under th e conditions of the MS analyses, no disulfide scrambling was observed; th e r3-ME mi xed di sulfide add uct is labi le under the moderately ac idic solution conditions used and was not found .
Epitope Structure Identification of a Monoclonal Antibody to Hi eRD
On th e basis of the primary stru ctu re characterisation, proteolytic epitope excision and extraction mass spectrometry were app lied to th e identifi cati o n of th e epitope recogn ised by th e monoclona l antibody (80 I) aga inst HI CRD. Proteo lytic excision MS analyses were carried out both with th e native HI CRD and th e reduced/alkylated anti gen, with two identica l sets of experiments with and without th e presence of calcium ions (Figure 4b, c) . After preparation of th e affinity column with th e immobilised antibody, epitope excision was carried out with the antibody-bo und H I CRD as described in the "Experimental", Following digestion with trypsin th e supematant containing unbound peptide fragments was removed, the co lumn washed extensively with buffer under binding conditions, and affi nity-bound peptides were eluted under acid ic conditions. The FTICR mass spectra of the a ffini ty -bound epitope peptide fracti on provided th e identification of two tryptic peptides, 5 TCCPVNWV EHER 1 (, (T2) conta ining th e vicinal Cys-6-Cys-7 disulfide linkage, and 17SCYWFSR 23 (T3) (Figure 4a, b) , These peptides identified th e location of th e epitope at th e N-tenninal domain within residues 5-23 of HI C RD . To investigate th e possible rol e of the Cys-6 and Cys-7 residues in the interaction with the antibody, epitope excision MS was additionally performed with the alkylated HI CRD and this led to the identification of the same epitope peptides, T2 and T3. Moreover, epitope extraction mass spectrometry, by subjecting a 50 ~lg aliquot of th e mixture of tryptic pep tides of the alkylated H J C RD to the affinity column, provided the identica l N-terminal fragments T2 and T3 (Fig ure 4c) , consistent with the previous results; this suggested that the Cys-6 and Cys-7 residues, albeit contained in th e iso lated ep itope peptid e T2, are not involved in the binding interaction . Ep itope excision MS performed with and without the presence of ca lcium ion s provided th e identification of identi cal epitope peptides, T2 and T3 (Figure 4b and c) , a result which is consistent with the binding site of th e antibody being remote from th e carbohydrate binding. The differences in abundances of th e two a ffinity-e luted epitope peptides were also identical to those found with th e epitope identification without the presence of ca lcium ; th e different abundances may be due to differences in re lative hydrophobicities of th e peptides as is frequently observed in MALDl-MS , and/or di ffe rences in re lative binding affi nities of the two peptides. T he proteolytic form ation and identification of the peptide T 2 showed that the Arg-16 residue is not shielded by the antibody binding, and suggested that Arg-16 is not involved in th e ep itope interaction .
A structure model based on the crystal structure of HI CRD suggests that th e amino acid residues of peptide T2 are accessible at th e prote in surface ( Figure 5) ; however, surface accessibilities from crysta l structure data of the antibody-immune complex are not available . The amino acid residues Thr-5 and Cys-6 have not been described in the X-ray structure [9] . The position of Arg-16 togeth er w ith G lu-15 within the loop connecting the ~ I strand 12YEH 14 and th e ~2 strand 17SCYWF21 appears to favour the tryptic cleavage observed at Arg-16. The first three res idues of the peptide T3 adjacent to Arg-16, Scr-J 7, Cys-18 and Tyr-19 are not accessib le whereas the last four amino acids 20WFSR 23 are exposed. Considering the tryptic cleavage sites and the location of Cys residues, the epitope comprising the peptides T2 and T3 may be forma ll y described by the two partial sequences RpYNWY EH 14 and 19YWFS22.
Affinity of Synthetic Epitope Peptides to the Antibody
On the basis of th e identification of th e ep itope stru cture, the characteri sation of th e binding a ffinity of the peptides T2 and T3 was a further aim of this study. The peptides T2 and T3 were synthes ised as described in the "Experimental", with th e cysteine residues protected by acetam idomethylation in order to prevent the formation of disulfide bridges fo ll owing deprotection and purification. The interacti on of th e synthetic peptides with the immobilised antibody was characterised by affi ni ty mass spectrometry . Binding of a mixture of the two peptides to th e antibody and MALDl -FTIC R-M S of the affinity e lu tion fraction provided th e recovery and identification of both peptides T2 and T3, consistent with the results of the epitope extraction MS (Supp lementary Figure 2) . Moreover, the affinity binding and elution of each individual peptide and MALDl-FTI CR-MS analysi s confirmed th at each peptide was binding independently to the antibody (data not shown).
Conclusions
Proteolytic ep itope eXCISIOn and extraction mass spectrometry of an antibody complex of the H I subunit of th e carbohydrate recognition domain of the asialog lycoprotein receptor HI CRD provide the identifi cation of the epitope comprising the N-tenninal domain 5T_ R23, with proteolytic access ibility observed at the R-16 and R-23 residues. The primary structure characterisation and identification of disulfide linkages of HI CRD was found to be an essen ti a l prerequisite for the identification of the antibody epitope. The epitope recognised by the antibody is located on the opposite side of th e carbohydrate binding site comprising the sequence 23YGln_Asn 264 , consistent with the lack of a neutralising effect of the antibody on carbohydrate binding; moreover, th e epitope binding by th e antibody was ascertained to be independent from the presence of calcium ions. These results confirm the feasibility of the BO I antibody as a molecular tool for the iso lation and functional characterisation of carbohydrate comp lexes of HI CRD [5] . Furthermore, proteolytic epitope excision mass spectrometry is shown here as a hi gh ly effic ient approach to reveal molecular detai ls of antigen-antibody interactions.
